Back to Authors

Agarwal, Suresh

https://orcid.org/0000-0003-3786-9773

A5066291807 | I2948539688

Mayo Clinic

AbbVie (United States)

Citations 1

Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

Blood | October 10, 2017 | Volume: 130 | Issue: 22 | Pages: 2401-2409

10.1182/blood-2017-06-788786 | PMID 29018077

Key Points Venetoclax monotherapy at a daily dose up to 1200 mg has an acceptable safety profile in patients with relapsed/refractory MM. Venetoclax monotherapy has demonstrated antimyeloma activity in patients with relapsed/refractory MM positive for t(11;14).